



**FOR BUSINESS/TRADE MEDIA ONLY**

## Dr Alberto Martinez appointed President and CEO of Mundipharma International Ltd

- Strategic leader to drive value, while expanding and diversifying portfolio through partnering opportunities
- Breadth of speciality, primary care and biosimilar healthcare experience

**Cambridge, UK, 13<sup>th</sup> December 2017** – The Mundipharma network of independent associated companies is pleased to announce Alberto Martinez as the newly-appointed President and Chief Executive Officer of Mundipharma International Ltd, with immediate effect. He succeeds Antony Mattessich who left the Mundipharma network after 12 years of service to pursue his career in the US.

Over the course of his career, Alberto has developed a deep understanding of healthcare and pharmaceuticals, offering a unique perspective across specialty and primary care portfolios. With his proven strategic, financial and operational capabilities together with his strong commitment to commercialization and growth, the Board of Directors is confident Alberto will enhance value for business partners, employees and patients alike. In addition, he will also focus on key strategic priorities that include expanding and diversifying the network's product portfolio, where the network is open to new alliance opportunities at all stages of asset maturity across the commercial platforms of specialist-driven primary care, specialty care (including emergency care, oncology and biosimilars) and established brands.

Alberto started his career in pharmaceutical sales in Spain before joining the Mundipharma network in 2003. Over the last 14 years he has transitioned through roles of increased leadership responsibility including General Manager of Mundipharma in Spain, where he led a corporate turnaround between 2008 and 2014, leading the company to achieve number 1 status in Great Places to Work where it remains to date. He has also led the UK commercial organization in the network, Napp Pharmaceuticals Ltd, where he drove a robust transformation program resulting in significant growth, including achieving market leadership for infliximab biosimilar, Remsima®. He was also given additional responsibility as Regional Director of Northern Europe before being appointed most recently in October 2016 as European Director of Commercial Operations.

Alberto is credited with leading a significant transformation across the European commercial organizations. As a result of this transformation, the Mundipharma European network is focused on



## **FOR BUSINESS/TRADE MEDIA ONLY**

delivering cost effective and sustainable growth through empowering local leadership and demonstrating commercial excellence across the commercial platforms. He also led the recent successful collaboration with Janssen that led to the European exclusive distribution deal for Invokana® and Vokanamet®, leading SGLT2 inhibitors for the treatment of type 2 diabetes.

Alberto holds a PhD in Medicinal Chemistry from Granada University and an Executive MBA from IE Business School.

Based from the Mundipharma network campus in Cambridge, in addition to European country oversight, in his new role Alberto will now also oversee European business development, HR and finance functions. Additionally, the functions of research and development, global manufacturing and supply chain and IT will also fall under Alberto's new remit. Under Alberto's leadership, the Mundipharma network in Europe will strengthen its focus on alliances. By continuing to foster already well-established and new alliances with healthcare providers, other pharmaceutical and biotechnology companies and with independently associated companies, the Mundipharma network will build inspiring places to grow for employees, securing a successful and sustainable future.

"I feel honored and privileged to be given the opportunity to lead the Mundipharma organizations in Europe in the next chapter of our evolution and success. I am committed to ensure that we remain ambitious and agile so we continue to bring valuable and innovative medicines to patients and healthcare providers as a successful, diversified and forward-thinking organization."

**-ends-**

### **About the Mundipharma network**

The Mundipharma global network of privately-owned independent associated companies was founded in 1956 by doctors, and now operates in over 120 countries worldwide. With the scale and resources equivalent to an integrated, mid-sized, multinational pharmaceutical company, we are focused on developing business partnerships to identify and accelerate meaningful technology across an increasingly diverse portfolio of therapy areas including respiratory, oncology, pain, and biosimilars. Consistent with our entrepreneurial heritage, we like to think we see what others don't by challenging conventional wisdom and asking different and challenging questions. By working with all our stakeholders, the Mundipharma network develops medicines that create value for patients, payers and wider healthcare systems.

For more information please visit: [www.mundipharma.com](http://www.mundipharma.com).



**FOR BUSINESS/TRADE MEDIA ONLY**

**For further information please contact:**

Susie Hackett on +44 (0) 7976 354277

Email: [Susie.hackett@mundipharma.com](mailto:Susie.hackett@mundipharma.com)